true1994-06-012024-03-27209POL_HV1Y2Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation.Li Y.Hui H.Burgess C.J.Price R.W.Sharp P.M.Hahn B.H.Shaw G.M.doi:10.1128/jvi.66.11.6587-6600.19921992J. Virol.666587-6600NUCLEOTIDE SEQUENCE [GENOMIC RNA]Proteolytic processing and particle maturation.Vogt V.M.doi:10.1007/978-3-642-80145-7_41996Curr. Top. Microbiol. Immunol.21495-131REVIEWStructural biology of HIV.Turner B.G.Summers M.F.doi:10.1006/jmbi.1998.23541999J. Mol. Biol.2851-32REVIEWMechanisms of retroviral recombination.Negroni M.Buc H.doi:10.1146/annurev.genet.35.102401.0905512001Annu. Rev. Genet.35275-302REVIEWRetroviral proteases.Dunn B.M.Goodenow M.M.Gustchina A.Wlodawer A.doi:10.1186/gb-2002-3-4-reviews30062002Genome Biol.3REVIEWS3006.1-REVIEWS3006.7REVIEWRole of HIV-1 Gag domains in viral assembly.Scarlata S.Carter C.doi:10.1016/s0005-2736(03)00163-92003Biochim. Biophys. Acta161462-72REVIEWSolution structure of the N-terminal zinc binding domain of HIV-1 integrase.Cai M.Zheng R.Caffrey M.Craigie R.Clore G.M.Gronenborn A.M.doi:10.1038/nsb0797-5671997Nat. Struct. Biol.4567-577STRUCTURE BY NMR OF 1148-1194NMR structure of the HIV-1 nucleocapsid protein bound to stem-loop SL2 of the psi-RNA packaging signal. Implications for genome recognition.Amarasinghe G.K.De Guzman R.N.Turner R.B.Chancellor K.J.Wu Z.R.Summers M.F.doi:10.1006/jmbi.2000.39792000J. Mol. Biol.301491-511STRUCTURE BY NMR OF 379-432Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.King N.M.Melnick L.Prabu-Jeyabalan M.Nalivaika E.A.Yang S.S.Gao Y.Nie X.Zepp C.Heefner D.L.Schiffer C.A.doi:10.1110/ps.255022002Protein Sci.11418-429X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 489-587 IN COMPLEX WITH INDINAVIR ANALOGSDiscovery and selection of TMC114, a next generation HIV-1 protease inhibitor.Surleraux D.L.Tahri A.Verschueren W.G.Pille G.M.de Kock H.A.Jonckers T.H.Peeters A.De Meyer S.Azijn H.Pauwels R.de Bethune M.P.King N.M.Prabu-Jeyabalan M.Schiffer C.A.Wigerinck P.B.doi:10.1021/jm049560p2005J. Med. Chem.481813-1822X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 489-587HIV drug resistance mutationshivdb; HIV drug resistance databaseA=381-4322.20A/B=489-5872.20A/B=489-5872.25A/B=489-5872.00A/B=489-587A=378-4321.35A/B=489-5872.20A/B=489-587A/B=1148-1194A/B=1148-1194A=278-363A=280-3631.71A=489-5872.25A=489-5871.71A=489-5871.70A/B=489-587P=130-1361.75A/B=489-587P=1025-10311.80A/B=489-587P=1145-11511.70A/B=489-587C=585-5911.60A/B=489-587C=488-4921.70A/B=489-5871.60A/B=489-5872.00A/B=489-587P=375-3811.80A/B=489-5872.25A=489-5872.05A/B=489-5871.80A/B=489-5871.50A/B=489-5873N-[2-hydroxy-1-indanyl]-5-[(2-tertiarybutylaminocarbonyl)-4(benzo[1,3]dioxol-5-ylmethyl)-piperazino]-4-hydroxy-2-(1-phenylethyl)-pentanamideHIV_retropepsin_likeRT_RtvAcid ProteasesHIV Type 1 Reverse Transcriptase, subunit A, domain 1Human Immunodeficiency Virus Type 1 Capsid ProteinImmunodeficiency lentiviruses, gag gene matrix protein p17Integrase, C-terminal domain superfamily, retroviralRibonuclease H-like superfamily/Ribonuclease HSingle helix binZinc finger, CCHC-typeAspartic_peptidase_ASDNA/RNA_pol_sfGag_p24_CIntegrase-like_NIntegrase_C_dom_sf_retrovirIntegrase_C_retrovirIntegrase_cat-coreIntegrase_Zn-bd_dom_NLentvrl_matrix_NMatrix_HIV/RSV_NPeptidase_A2_catPeptidase_aspartic_dom_sfRetropepsin-like_cat_domRetropepsinsRetrov_capsid_CRetrov_capsid_NRetrovr_matrixRev_trsase/Diguanyl_cyclaseRNaseH-like_sfRNaseH_domainRNaseH_sfRT_domRVT_connectRVT_thumbZnf_CCHCZnf_CCHC_sfENDOGENOUS RETROVIRUS GROUP K MEMBER POL PROTEINRNA-DIRECTED DNA POLYMERASE-RELATEDGag_p17Gag_p24_CIN_DBD_CIntegrase_ZnRNase_HrveRVPRVT_1RVT_connectRVT_thumbzf-CCHCHIV1MATRIXZnF_C2HCAcid proteasesDNA-binding domain of retroviral integraseDNA/RNA polymerasesN-terminal Zn binding domain of HIV integraseRetroviral matrix proteinsRetrovirus capsid dimerization domain-likeRetrovirus capsid protein, N-terminal core domainRetrovirus zinc finger-like domainsRibonuclease H-likeASP_PROT_RETROVASP_PROTEASEINTEGRASEINTEGRASE_DBDRNASE_H_1RT_POLZF_CCHCZF_INTEGRASEGag-Pol polyproteinPr160Gag-PolMatrix protein p17MACapsid protein p24CASpacer peptide 1SP1p2Nucleocapsid protein p7NCTransframe peptideTFp6-polp6*Protease3.4.23.16PRRetropepsinReverse transcriptase/ribonuclease H2.7.7.492.7.7.73.1.26.13Exoribonuclease H3.1.13.2p66 RTp51 RTp15IntegraseIN2.7.7.-3.1.-.-gag-polMediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA.Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates in gRNA dimerization, packaging, tRNA incorporation and virion assembly.Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response. Also mediates cleavage of host YTHDF3. Mediates cleavage of host CARD8, thereby activating the CARD8 inflammasome, leading to the clearance of latent HIV-1 in patient CD4(+) T-cells after viral reactivation; in contrast, HIV-1 can evade CARD8-sensing when its protease remains inactive in infected cells prior to viral budding (By similarity).Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.Binds 2 magnesium ions for reverse transcriptase polymerase activity.Binds 2 magnesium ions for ribonuclease H (RNase H) activity. Substrate-binding is a precondition for magnesium binding.Magnesium ions are required for integrase activity. Binds at least 1, maybe 2 magnesium ions.Protease: The viral protease is inhibited by many synthetic protease inhibitors (PIs), such as amprenavir, atazanavir, indinavir, loprinavir, nelfinavir, ritonavir and saquinavir. Use of protease inhibitors in tritherapy regimens permit more ambitious therapeutic strategies. Reverse transcriptase/ribonuclease H: RT can be inhibited either by nucleoside RT inhibitors (NRTIs) or by non nucleoside RT inhibitors (NNRTIs). NRTIs act as chain terminators, whereas NNRTIs inhibit DNA polymerization by binding a small hydrophobic pocket near the RT active site and inducing an allosteric change in this region. Classical NRTIs are abacavir, adefovir (PMEA), didanosine (ddI), lamivudine (3TC), stavudine (d4T), tenofovir (PMPA), zalcitabine (ddC), and zidovudine (AZT). Classical NNRTIs are atevirdine (BHAP U-87201E), delavirdine, efavirenz (DMP-266), emivirine (I-EBU), and nevirapine (BI-RG-587). The tritherapies used as a basic effective treatment of AIDS associate two NRTIs and one NNRTI.Homotrimer; further assembles as hexamers of trimers (By similarity). Interacts with gp41 (via C-terminus) (By similarity). Interacts with host CALM1; this interaction induces a conformational change in the Matrix protein, triggering exposure of the myristate group (By similarity). Interacts with host AP3D1; this interaction allows the polyprotein trafficking to multivesicular bodies during virus assembly (By similarity). Part of the pre-integration complex (PIC) which is composed of viral genome, matrix protein, Vpr and integrase (By similarity).Homodimer; the homodimer further multimerizes as homohexamers or homopentamers. Interacts with human PPIA/CYPA (By similarity); This interaction stabilizes the capsid. Interacts with human NUP153 (By similarity). Interacts with host PDZD8; this interaction stabilizes the capsid (By similarity). Interacts with monkey TRIM5; this interaction destabilizes the capsid (By similarity).Homodimer, whose active site consists of two apposed aspartic acid residues.Heterodimer of p66 RT and p51 RT (RT p66/p51) (By similarity). Heterodimerization of RT is essential for DNA polymerase activity (By similarity). The overall folding of the subdomains is similar in p66 RT and p51 RT but the spatial arrangements of the subdomains are dramatically different (By similarity).Homotetramer; may further associate as a homohexadecamer (By similarity). Part of the pre-integration complex (PIC) which is composed of viral genome, matrix protein, Vpr and integrase. Interacts with human SMARCB1/INI1 and human PSIP1/LEDGF isoform 1. Interacts with human KPNA3; this interaction might play a role in nuclear import of the pre-integration complex (By similarity). Interacts with human NUP153; this interaction might play a role in nuclear import of the pre-integration complex (By similarity).These locations are linked to virus assembly sites. The main location is the cell membrane, but under some circumstances, late endosomal compartments can serve as productive sites for virion assembly.Nuclear at initial phase, cytoplasmic at assembly.Translation results in the formation of the Gag polyprotein most of the time. Ribosomal frameshifting at the gag-pol genes boundary occurs at low frequency and produces the Gag-Pol polyprotein. This strategy of translation probably allows the virus to modulate the quantity of each viral protein. Maintenance of a correct Gag to Gag-Pol ratio is essential for RNA dimerization and viral infectivity.RT is structured in five subdomains: finger, palm, thumb, connection and RNase H. Within the palm subdomain, the 'primer grip' region is thought to be involved in the positioning of the primer terminus for accommodating the incoming nucleotide. The RNase H domain stabilizes the association of RT with primer-template.The tryptophan repeat motif is involved in RT p66/p51 dimerization (By similarity).The core domain contains the D-x(n)-D-x(35)-E motif, named for the phylogenetically conserved glutamic acid and aspartic acid residues and the invariant 35 amino acid spacing between the second and third acidic residues. Each acidic residue of the D,D(35)E motif is independently essential for the 3'-processing and strand transfer activities of purified integrase protein.Specific enzymatic cleavages by the viral protease yield mature proteins. The protease is released by autocatalytic cleavage. The polyprotein is cleaved during and after budding, this process is termed maturation. Proteolytic cleavage of p66 RT removes the RNase H domain to yield the p51 RT subunit. Nucleocapsid protein p7 might be further cleaved after virus entry.Tyrosine phosphorylated presumably in the virion by a host kinase. Phosphorylation is apparently not a major regulator of membrane association.Phosphorylated possibly by host MAPK1; this phosphorylation is necessary for Pin1-mediated virion uncoating.Methylated by host PRMT6, impairing its function by reducing RNA annealing and the initiation of reverse transcription.Error-prone enzyme that lacks a proof-reading function. High mutations rate is a direct consequence of this characteristic. RT also displays frequent template switching leading to high recombination rate. Recombination mostly occurs between homologous regions of the two copackaged RNA genomes. If these two RNA molecules derive from different viral strains, reverse transcription will give rise to highly recombinated proviral DNAs.HIV-1 lineages are divided in three main groups, M (for Major), O (for Outlier), and N (for New, or Non-M, Non-O). The vast majority of strains found worldwide belong to the group M. Group O seems to be endemic to and largely confined to Cameroon and neighboring countries in West Central Africa, where these viruses represent a small minority of HIV-1 strains. The group N is represented by a limited number of isolates from Cameroonian persons. The group M is further subdivided in 9 clades or subtypes (A to D, F to H, J and K).Resistance to inhibitors associated with mutations are observed both in viral protease and in reverse transcriptase. Most of the time, single mutations confer only a modest reduction in drug susceptibility. Combination of several mutations is usually required to develop a high-level drug resistance. These mutations are predominantly found in clade B viruses and not in other genotypes. They are listed in the clade B representative isolate HXB2 (AC P04585).Produced by -1 ribosomal frameshifting.Removed; by host1Gag-Pol polyprotein16184921435Matrix protein p1714716132Capsid protein p2425593133363Spacer peptide 1364377Nucleocapsid protein p76397378432Transframe peptide433440p6-pol5510441488Protease10804489587Reverse transcriptase/ribonuclease H643835881147p51 RT512751027p15131261028Integrase321261148Peptidase A2508577Reverse transcriptase631821RNase H type-110211144Integrase catalytic12011351CCHC-type 1390407CCHC-type 2411428Integrase-type11501191Integrase-type13701417Interaction with Gp41731Interaction with host CALM1843Interaction with host AP3D11219Interaction with membrane phosphatidylinositol 4,5-bisphosphate and RNA1433Interaction with membrane phosphatidylinositol 4,5-bisphosphate7377Disordered106128Interaction with human PPIA/CYPA and NUP153189227Dimerization/Multimerization of capsid protein p24277Dimerization of protease493Dimerization of protease537543Dimerization of protease576RT 'primer grip'814822Nuclear export signal1622Nuclear localization signal2632Tryptophan repeat motif9851001For protease activity; shared with dimeric partner51369777277310301065108511361159116311871190121112631299Cleavage; by viral proteaseCis/trans isomerization of proline peptide bond; by human PPIA/CYPA221222Cleavage; by viral proteaseCleavage; by viral proteaseCleavage; by viral proteaseCleavage; by viral proteaseCleavage; by viral proteaseCleavage; by viral proteaseEssential for RT p66/p51 heterodimerization988Essential for RT p66/p51 heterodimerizationCleavage; by viral protease; partialCleavage; by viral proteasePhosphotyrosine; by hostN-myristoyl glycine; by host2822842933053073093113243283373433493523553803883933953984004024044104134144174234254954985035065125175235315405545575665755785795825845861149115511611164116611731177118611881catalytic; for reverse transcriptase activity2catalytic; for RNase H activity3catalytic; for integrase activitytrue3VBP12007-01-2331619802bd9a81094ac6b8840ccacca0424c225Gag-Pol polyproteinMGARASVLSAGELDKWEKIRLRPGGKKQYRLKHIVWASRELERFAVDPGLLETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQKIEVKDTKEALEKIEEEQNKSKKKAQQAAADTGNSSQVSQNYPIVQNLQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCWKCGKEGHQMKDCTERQANFLREDLAFPQGKARKFSSEQTRANSPIRRERQVWRRDNNSLSEAGADRQGTVSFSFPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTTILEPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARTRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIGAETFYVDGAANRETKLGKAGYVTNKGRQKVVSLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDRSESELVSQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVLFLDGIDKAQEEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVTTIHTDNGSNFTSATVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVAGRQDEDGag polyproteintruetruetruetruetruetruetruetruetruetruetruetruetruetruetruetruetrue